Sinopharm

The incidence of adverse effects from Sinopharm's two inactivated COVID-19 vaccines is 1.06 percent, according to a report on Wednesday based on emergency use of the two vaccines in China on more than 500,000 people as of December 1, which is far lower than the phase II clinical trial results.  

The two vaccines were separately developed by Sinopharm's Beijing and Wuhan institutes. The Beijing institute vaccine was approved for emergency use in China on June 30, 2020. The Wuhan institute one was approved on July 23, 2020.

The adverse effect incidence of the two in phase II clinical trials was 13 percent and 19 percent, respectively.

According to the Wednesday report, as of December 1, 2020, among the 519,543 people who had accepted the vaccines, no serious side effects were reported, proving the safety of the vaccines.     

The overall incidence of adverse effects is 1.06 percent. The figure was higher among women at 1.58 percent, while for men it was 0.72 percent. Among people aged 60 and above, the incidence was 0.32 percent, according to the report. 

The 519,543 recipients included diplomats, workers on Belt and Road projects, Chinese students studying overseas, medical workers, customs personnel and government workers facing a high infection risk.

Global Times